Core Viewpoint - Rapport Therapeutics is set to announce topline results for the Phase 2a trial of its investigational drug RAP-219, aimed at treating drug-resistant focal onset seizures, during a conference call on September 8, 2025 [1]. Company Overview - Rapport Therapeutics is a clinical-stage biotechnology company focused on developing small molecule precision medicines for neurological and psychiatric disorders [3]. - The company’s founders have made significant discoveries regarding receptor associated proteins (RAPs) in the brain, which underpin the RAP technology platform [3]. - The lead investigational drug, RAP-219, is designed to achieve neuroanatomical specificity by selectively targeting a RAP expressed in specific brain regions [3]. - In addition to drug-resistant focal onset seizures, RAP-219 is being explored as a potential treatment for bipolar mania and diabetic peripheral neuropathic pain [3]. - The company is also engaged in preclinical and late-stage discovery programs targeting chronic pain and hearing disorders [3].
Rapport Therapeutics to Announce Topline Results for RAP-219 Phase 2a Trial in Focal Onset Seizures on Monday, September 8, 2025